Biophytis Targets Mobility Restoration in Sarcopenia Patients
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Apr 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: biotechnology, clinical-trials, drug-development, sarcopenia
TL;DR
Biophytis pushing Sarcone for sarcopenia mobility, aiming for better patient outcomes.
AI Summary
On April 22, 2025, Biophytis S.A. announced its target of restoring mobility in patients suffering from sarcopenia, a degenerative muscle disease. The company is advancing its drug candidate, Sarcone, through clinical trials, with a focus on improving the quality of life for affected individuals.
Why It Matters
This filing indicates Biophytis's continued focus on developing treatments for sarcopenia, a condition affecting millions globally, potentially impacting patient care and the pharmaceutical market for age-related diseases.
Risk Assessment
Risk Level: medium — The company is in the clinical trial phase for its drug candidate, meaning success is not guaranteed and regulatory approval is still pending.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Sarcone (drug_candidate) — Drug being developed for sarcopenia
- Stanislas Veillet (person) — Contact person for Biophytis S.A.
- April 22, 2025 (date) — Date of report and press release
FAQ
What is the primary goal of Biophytis S.A. as stated in this report?
Biophytis S.A. targets the restoration of mobility in patients suffering from sarcopenia.
What is the name of Biophytis S.A.'s drug candidate mentioned?
The drug candidate is referred to as Sarcone.
When was this report filed with the SEC?
This report was filed on April 22, 2025.
What is the principal executive office address of Biophytis S.A.?
The principal executive office is located at Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France.
Does Biophytis S.A. file annual reports under Form 20-F?
Yes, the company indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 22, 2025 by Stanislas Veillet regarding Biophytis SA.